NCT00664222View on ClinicalTrials.gov

Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

December 31, 2005

Conditions
Chronic Stable Heart Failure
Interventions
DRUG

spironolactone + furosemide

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks

All Listed Sponsors
lead

Tottori University Hospital

OTHER

NCT00664222 - Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF) | Biotech Hunter | Biotech Hunter